Cargando…
Comparison of therapeutic efficacy and toxicity of docetaxel, cisplatin, and fluorouracil (TPF)-based induction chemotherapy plus concurrent chemoradiotherapy and chemoradiotherapy alone in locally advanced nasopharyngeal carcinoma
PURPOSE: In recent years, docetaxel, cisplatin, and fluorouracil (TPF)-based induction chemotherapy plus concurrent chemoradiotherapy (CCRT) has been commonly applied for locally advanced nasopharyngeal carcinoma (LA-NPC). However, whether TPF+CCRT regimen is the best choice for LA-NPC remains uncle...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8542149/ https://www.ncbi.nlm.nih.gov/pubmed/34678878 http://dx.doi.org/10.1097/MD.0000000000027475 |
_version_ | 1784589381091196928 |
---|---|
author | Chen, Ruijuan Lu, Yongkai Zhang, Yuemei He, Ruixin Tang, Fengwen Yuan, Wei Li, Yi Zhang, Xiaowei |
author_facet | Chen, Ruijuan Lu, Yongkai Zhang, Yuemei He, Ruixin Tang, Fengwen Yuan, Wei Li, Yi Zhang, Xiaowei |
author_sort | Chen, Ruijuan |
collection | PubMed |
description | PURPOSE: In recent years, docetaxel, cisplatin, and fluorouracil (TPF)-based induction chemotherapy plus concurrent chemoradiotherapy (CCRT) has been commonly applied for locally advanced nasopharyngeal carcinoma (LA-NPC). However, whether TPF+CCRT regimen is the best choice for LA-NPC remains unclear. This meta-analysis aims to elucidate and compare the efficacy and toxicity of TPF+CCRT versus CCRT alone for LA-NPC. METHODS: Two investigators independently and systematically searched relevant studies available on PubMed, Embase, Cochrane Library, and Web of Science published before January 7, 2021. Data were extracted from eligible studies for assessing their qualities, and calculating pooled hazard ratios (HR), odds ratio (OR) and 95% confidence intervals (CI) using Review Manager software 5.3 (RevMan 5.3). RESULTS: Five studies involving 759 LA-NPC patients were analyzed in the meta-analysis. Compared to CCRT alone, TPF-based IC plus CCRT significantly improved overall survival (OS) (HR = 0.53, 95% CI: 0.35–0.81, P = .003), progression-free survival (PFS) (HR = 0.63, 95% CI: 0.46–0.86, P = .004), distant metastasis-free survival (DMFS) (HR = 0.58, 95% CI: 0.39–0.86, P = .008), and locoregional failure-free survival (LRFFS) (HR 0.62, 95% CI: 0.43–0.90, P = .01). In addition, TPF-based IC plus CCRT mainly increased risks of grade 3/4 acute hematological toxicity and non-hematological toxicities like leukopenia (OR = 1.84, 95% CI: 0.42–8.03, P = .42), neutropenia (OR = 1.78, 95% CI: 0.23–13.82, P = .58), thrombocytopenia (OR = 1.76, 95% CI: 0.53–5.81, P = .35), febrile neutropenia (OR = 2.76, 95% CI: 0.07–101.89, P = .58), vomiting (OR = 18.94, 95% CI: 0.99–362.02, P = .05) and dry mouth (OR = 2.23, 95% CI: 0.22–22.57, P = .50), which were uncomplicated and manageable. CONCLUSIONS: TPF + CCRT is superb than CCRT alone for the management of LA-NPC. However, TPF+CCRT increases the incidences of grade 3/4 acute hematological toxicity and some non-hematological toxicities. |
format | Online Article Text |
id | pubmed-8542149 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Lippincott Williams & Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-85421492021-10-25 Comparison of therapeutic efficacy and toxicity of docetaxel, cisplatin, and fluorouracil (TPF)-based induction chemotherapy plus concurrent chemoradiotherapy and chemoradiotherapy alone in locally advanced nasopharyngeal carcinoma Chen, Ruijuan Lu, Yongkai Zhang, Yuemei He, Ruixin Tang, Fengwen Yuan, Wei Li, Yi Zhang, Xiaowei Medicine (Baltimore) 5700 PURPOSE: In recent years, docetaxel, cisplatin, and fluorouracil (TPF)-based induction chemotherapy plus concurrent chemoradiotherapy (CCRT) has been commonly applied for locally advanced nasopharyngeal carcinoma (LA-NPC). However, whether TPF+CCRT regimen is the best choice for LA-NPC remains unclear. This meta-analysis aims to elucidate and compare the efficacy and toxicity of TPF+CCRT versus CCRT alone for LA-NPC. METHODS: Two investigators independently and systematically searched relevant studies available on PubMed, Embase, Cochrane Library, and Web of Science published before January 7, 2021. Data were extracted from eligible studies for assessing their qualities, and calculating pooled hazard ratios (HR), odds ratio (OR) and 95% confidence intervals (CI) using Review Manager software 5.3 (RevMan 5.3). RESULTS: Five studies involving 759 LA-NPC patients were analyzed in the meta-analysis. Compared to CCRT alone, TPF-based IC plus CCRT significantly improved overall survival (OS) (HR = 0.53, 95% CI: 0.35–0.81, P = .003), progression-free survival (PFS) (HR = 0.63, 95% CI: 0.46–0.86, P = .004), distant metastasis-free survival (DMFS) (HR = 0.58, 95% CI: 0.39–0.86, P = .008), and locoregional failure-free survival (LRFFS) (HR 0.62, 95% CI: 0.43–0.90, P = .01). In addition, TPF-based IC plus CCRT mainly increased risks of grade 3/4 acute hematological toxicity and non-hematological toxicities like leukopenia (OR = 1.84, 95% CI: 0.42–8.03, P = .42), neutropenia (OR = 1.78, 95% CI: 0.23–13.82, P = .58), thrombocytopenia (OR = 1.76, 95% CI: 0.53–5.81, P = .35), febrile neutropenia (OR = 2.76, 95% CI: 0.07–101.89, P = .58), vomiting (OR = 18.94, 95% CI: 0.99–362.02, P = .05) and dry mouth (OR = 2.23, 95% CI: 0.22–22.57, P = .50), which were uncomplicated and manageable. CONCLUSIONS: TPF + CCRT is superb than CCRT alone for the management of LA-NPC. However, TPF+CCRT increases the incidences of grade 3/4 acute hematological toxicity and some non-hematological toxicities. Lippincott Williams & Wilkins 2021-10-22 /pmc/articles/PMC8542149/ /pubmed/34678878 http://dx.doi.org/10.1097/MD.0000000000027475 Text en Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. http://creativecommons.org/licenses/by/4.0 (https://creativecommons.org/licenses/by/4.0/) |
spellingShingle | 5700 Chen, Ruijuan Lu, Yongkai Zhang, Yuemei He, Ruixin Tang, Fengwen Yuan, Wei Li, Yi Zhang, Xiaowei Comparison of therapeutic efficacy and toxicity of docetaxel, cisplatin, and fluorouracil (TPF)-based induction chemotherapy plus concurrent chemoradiotherapy and chemoradiotherapy alone in locally advanced nasopharyngeal carcinoma |
title | Comparison of therapeutic efficacy and toxicity of docetaxel, cisplatin, and fluorouracil (TPF)-based induction chemotherapy plus concurrent chemoradiotherapy and chemoradiotherapy alone in locally advanced nasopharyngeal carcinoma |
title_full | Comparison of therapeutic efficacy and toxicity of docetaxel, cisplatin, and fluorouracil (TPF)-based induction chemotherapy plus concurrent chemoradiotherapy and chemoradiotherapy alone in locally advanced nasopharyngeal carcinoma |
title_fullStr | Comparison of therapeutic efficacy and toxicity of docetaxel, cisplatin, and fluorouracil (TPF)-based induction chemotherapy plus concurrent chemoradiotherapy and chemoradiotherapy alone in locally advanced nasopharyngeal carcinoma |
title_full_unstemmed | Comparison of therapeutic efficacy and toxicity of docetaxel, cisplatin, and fluorouracil (TPF)-based induction chemotherapy plus concurrent chemoradiotherapy and chemoradiotherapy alone in locally advanced nasopharyngeal carcinoma |
title_short | Comparison of therapeutic efficacy and toxicity of docetaxel, cisplatin, and fluorouracil (TPF)-based induction chemotherapy plus concurrent chemoradiotherapy and chemoradiotherapy alone in locally advanced nasopharyngeal carcinoma |
title_sort | comparison of therapeutic efficacy and toxicity of docetaxel, cisplatin, and fluorouracil (tpf)-based induction chemotherapy plus concurrent chemoradiotherapy and chemoradiotherapy alone in locally advanced nasopharyngeal carcinoma |
topic | 5700 |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8542149/ https://www.ncbi.nlm.nih.gov/pubmed/34678878 http://dx.doi.org/10.1097/MD.0000000000027475 |
work_keys_str_mv | AT chenruijuan comparisonoftherapeuticefficacyandtoxicityofdocetaxelcisplatinandfluorouraciltpfbasedinductionchemotherapyplusconcurrentchemoradiotherapyandchemoradiotherapyaloneinlocallyadvancednasopharyngealcarcinoma AT luyongkai comparisonoftherapeuticefficacyandtoxicityofdocetaxelcisplatinandfluorouraciltpfbasedinductionchemotherapyplusconcurrentchemoradiotherapyandchemoradiotherapyaloneinlocallyadvancednasopharyngealcarcinoma AT zhangyuemei comparisonoftherapeuticefficacyandtoxicityofdocetaxelcisplatinandfluorouraciltpfbasedinductionchemotherapyplusconcurrentchemoradiotherapyandchemoradiotherapyaloneinlocallyadvancednasopharyngealcarcinoma AT heruixin comparisonoftherapeuticefficacyandtoxicityofdocetaxelcisplatinandfluorouraciltpfbasedinductionchemotherapyplusconcurrentchemoradiotherapyandchemoradiotherapyaloneinlocallyadvancednasopharyngealcarcinoma AT tangfengwen comparisonoftherapeuticefficacyandtoxicityofdocetaxelcisplatinandfluorouraciltpfbasedinductionchemotherapyplusconcurrentchemoradiotherapyandchemoradiotherapyaloneinlocallyadvancednasopharyngealcarcinoma AT yuanwei comparisonoftherapeuticefficacyandtoxicityofdocetaxelcisplatinandfluorouraciltpfbasedinductionchemotherapyplusconcurrentchemoradiotherapyandchemoradiotherapyaloneinlocallyadvancednasopharyngealcarcinoma AT liyi comparisonoftherapeuticefficacyandtoxicityofdocetaxelcisplatinandfluorouraciltpfbasedinductionchemotherapyplusconcurrentchemoradiotherapyandchemoradiotherapyaloneinlocallyadvancednasopharyngealcarcinoma AT zhangxiaowei comparisonoftherapeuticefficacyandtoxicityofdocetaxelcisplatinandfluorouraciltpfbasedinductionchemotherapyplusconcurrentchemoradiotherapyandchemoradiotherapyaloneinlocallyadvancednasopharyngealcarcinoma |